Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 9, 2007, Pages 1467-1479

  Mosconi, Lisa ^a   Tsui, Wai H ^a,b   Rusinek, Henry ^a   De Santi, Susan ^a   Li, Yi ^a   Wang, Gene Jack ^d   Pupi, Alberto ^c   Fowler, Joanna ^d   De Leon, Mony J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Alzheimer's disease; Dynamic FDG PET imaging; Hippocampus; Kinetic rate constants; Metabolic rate of glucose; Posterior cingulate cortex

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTERIAL BLOOD; ARTICLE; AUTORADIOGRAPHY; BRAIN METABOLISM; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PROTEIN PHOSPHORYLATION; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION; FEMALE; GLUCOSE; HIPPOCAMPUS; HUMANS; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY;

EID: 34548170737     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0406-5     Document Type: Article

References (34)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
2. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-68.
3. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-80.
4. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impiarment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-42.
5. De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Boppana M, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-39.
6. 18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966-71.
7. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003;54:343-51.
8. Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in mild cognitive impairment and Alzheimer's disease: automated FDG-PET image analysis. Neurology 2005;64:1860-7.
9. Mosconi L, De Santi S, Li Y, Li J, Zhan J, Tsui WH, et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med 2006;33:210-21.
10. Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 2006;47:1778-86.
11. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
12. Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-7.
13. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med 2003;30:1104-13.
14. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-flouro-2-deoxy-d-glucose:validation of method. Ann Neurol 1979;6:371-88.
15. Patlak C, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
16. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
17. 11C]deoxyglucose. J Cereb Blood Flow Metab 1985;5:179-92.
18. Friedland RP, Jagust WJ, Huesman RH, Koss E, Knittel B, Mathis CA, et al. Regional cerebral glucose transport and utilization in Alzheimer's disease. Neurology 1989;39:1427-34.
19. Jagust WJ, Seab JP, Huesman RH, Valk PE, Mathis CA, Reed BR, et al. Diminished glucose transport in Alzheimer's disease: dynamic PET studies. J Cereb Blood Flow Metab 1991;11:323-30.
20. Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J Nucl Med 1996;37:201-8.
21. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, D.C.: American Psychiatric Association; 1994.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
23. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiat 1982;139:1136-9.
24. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
25. Lezak MD. Neuropsychological assessment, 3rd edn. New York: Oxford University Press; 1995.
26. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-22.
27. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17:536-46.
28. Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571-83.
29. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer's disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995;19:541-7.
30. Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport 2001;12:851-5.
31. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332-40.
32. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 1997;38:925-8.
33. Rapoport SI, Grady CL. Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer's disease. Int J Neurosci 1993;70:36-59.
34. Pietrini P, Furey ML, Alexander GE, Mentis MJ, Dani A, Guazzelli M, et al. Association between brain functional failure and dementia severity in Alzheimer's disease: resting versus stimulation PET study. Am J Psychiatry 1999;156:470-3.